Patents by Inventor Dominik Feuerbach

Dominik Feuerbach has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREM2 STABILIZING ANTIBODIES
    Publication number: 20230167174
    Abstract: The present invention provides antibodies that bind to and stabilize human Triggering Receptor Expressed on Myeloid cells 2 (TREM2) protein and methods of using these antibodies.
    Type: Application
    Filed: September 23, 2022
    Publication date: June 1, 2023
    Inventors: Verena BRAND, Dominik FEUERBACH, Fabrizio GASPARINI, Nathalie GEORGE, Eveline SCHAADT, Derya SHIMSHEK, Honnappa SRINIVAS, Markus WALDHUBER, Rainer WILCKEN
  • TREM2 stabilizing antibodies
    Patent number: 11492402
    Abstract: The present invention provides antibodies that bind to and stabilize human Triggering Receptor Expressed on Myeloid cells 2 (TREM2) protein and methods of using these antibodies.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: November 8, 2022
    Assignee: NOVARTIS AG
    Inventors: Verena Brand, Dominik Feuerbach, Fabrizio Gasparini, Nathalie George, Eveline Schaadt, Derya Shimshek, Honnappa Srinivas, Markus Waldhuber, Rainer Wilcken
  • BIOMARKER PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT
    Publication number: 20220316011
    Abstract: The invention provides methods for predicting therapeutic responsiveness of a subject suffering from cognitive impairments or dysfunctions, psychotic and/or neurodegenerative disorders to an alpha 7 nicotinic acetylcholine receptor activator treatment.
    Type: Application
    Filed: June 1, 2022
    Publication date: October 6, 2022
    Inventors: Dominik Feuerbach, Baltazar Gomez-Mancilla, Yunsheng He, Donald Johns, Cristina Lopez-Lopez, Kevin Hall McAllister, Nicole Pezous, Lisa Sandford, Markus Weiss
  • ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS
    Publication number: 20220211679
    Abstract: The invention concerns the use of certain alpha 7 nicotinic acetylcholine receptor agonists for the treatment, amelioration, prevention or delay of progression of fatigue, narcolepsy, excessive daytime sleepiness, nocturnal sleep disturbance, and/or cataplexy.
    Type: Application
    Filed: March 21, 2022
    Publication date: July 7, 2022
    Inventors: Markus FENDT, Dominik FEUERBACH, Donald JOHNS, Cristina LOPEZ-LOPEZ, Kevin Hall MCALLISTER, Judit SOVAGO, Markus WEISS, Baltazar GOMEZ-MANCILLA
  • Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment
    Patent number: 11359241
    Abstract: The invention provides methods for predicting therapeutic responsiveness of a subject suffering from cognitive impairments or dysfunctions, psychotic and/or neurodegenerative disorders to an alpha 7 nicotinic acetylcholine receptor activator treatment.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: June 14, 2022
    Assignee: Novartis AG
    Inventors: Dominik Feuerbach, Baltazar Gomez-Mancilla, Yunsheng He, Donald Johns, Cristina Lopez-Lopez, Kevin Hall McAllister, Nicole Pezous, Lisa Sandford, Markus Weiss
  • Use of alpha 7 nicotinic acetylcholine receptor agonists
    Patent number: 11311525
    Abstract: The invention concerns the use of certain alpha 7 nicotinic acetylcholine receptor agonist for the facilitation of emergence from general anesthesia.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: April 26, 2022
    Assignee: Novartis AG
    Inventors: Markus Fendt, Dominik Feuerbach, Sjoerd Johannes Finnema, Christer Halldin, Donald Johns, Cristina Lopez-Lopez, Kevin Hall McAllister, Judit Sovago, Markus Weiss
  • USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS
    Publication number: 20210338621
    Abstract: The invention concerns the use of a nicotinic acetylcholine receptor alpha 7 activators for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease.
    Type: Application
    Filed: July 16, 2021
    Publication date: November 4, 2021
    Inventors: Therese Di Paolo, Dominik Feuerbach, Baltazar Gomez-Mancilla, Donald Johns
  • Use of nicotinic acetylcholine receptor alpha 7 activators
    Patent number: 11096916
    Abstract: The invention concerns the use of a nicotinic acetylcholine receptor alpha 7 activators for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: August 24, 2021
    Assignee: Novartis AG
    Inventors: Therese Di Paolo, Dominik Feuerbach, Baltazar Gomez-Mancilla, Donald Johns
  • TREM2 MUTANTS RESISTANT TO SHEDDASE CLEAVAGE
    Publication number: 20200207830
    Abstract: Provided herein are methods and compositions related to TREM2 mutants resistant to sheddase cleavage, e.g., human TREM2 mutants resistant to sheddase cleavage, and nucleic acids encoding such TREM2 mutants resistant to sheddase cleavage.
    Type: Application
    Filed: July 26, 2018
    Publication date: July 2, 2020
    Inventors: Dominik FEUERBACH, Ulf NEUMANN
  • TREM2 STABILIZING ANTIBODIES
    Publication number: 20200140545
    Abstract: The present invention provides antibodies that bind to and stabilize human Triggering Receptor Expressed on Myeloid cells 2 (TREM2) protein and methods of using these antibodies.
    Type: Application
    Filed: October 14, 2019
    Publication date: May 7, 2020
    Inventors: Verena BRAND, Dominik FEUERBACH, Fabrizio GASPARINI, Nathalie GEORGE, Eveline SCHAADT, Derya SHIMSHEK, Honnappa SRINIVAS, Markus WALDHUBER, Rainer WILCKEN
  • USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS
    Publication number: 20200108035
    Abstract: The invention concerns the use of a nicotinic acetylcholine receptor alpha 7 activators for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease.
    Type: Application
    Filed: December 4, 2019
    Publication date: April 9, 2020
    Inventors: Therese Di Paolo, Dominik Feuerbach, Baltazar Gomez-Mancilla, Donald Johns
  • Use of nicotinic acetylcholine receptor alpha 7 activators
    Patent number: 10537539
    Abstract: The invention concerns the use of a nicotinic acetylcholine receptor alpha 7 activators for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease.
    Type: Grant
    Filed: September 22, 2010
    Date of Patent: January 21, 2020
    Assignee: NOVARTIS AG
    Inventors: Thérèse Di Paolo, Dominik Feuerbach, Baltazar Gomez-Mancilla, Donald Johns
  • AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS
    Publication number: 20190083474
    Abstract: The present invention relates to 1-aza-bicycloalkyl derivatives of formula I, wherein X is CH2 or a single bond; Y is a group of formula and wherein R has the meanings as defined in the specification, which compounds are alpha 7 nicotinic acetylcholine receptor (nAChR) agonists; to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
    Type: Application
    Filed: November 15, 2018
    Publication date: March 21, 2019
    Inventors: Dominik Feuerbach, Konstanze Hurth, Timothy John Ritchie, Rochdi Bouhelal
  • AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS
    Publication number: 20180078536
    Abstract: The present invention relates to 1-aza-bicycloalkyl derivatives of formula I, wherein X is CH2 or a single bond; Y is a group of formula and wherein R has the meanings as defined in the specification, which compounds are alpha 7 nicotinic acetylcholine receptor (nAChR) agonists; to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
    Type: Application
    Filed: November 21, 2017
    Publication date: March 22, 2018
    Inventors: Dominik Feuerbach, Konstanze Hurth, Timothy John Ritchie, Rochdi Bouhelal
  • BIOMARKERS PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT
    Publication number: 20180037957
    Abstract: The invention provides methods for predicting therapeutic responsiveness of a subject suffering from cognitive impairments or dysfunctions, psychotic and/or neurodegenerative disorders to an alpha 7 nicotinic acetylcholine receptor activator treatment.
    Type: Application
    Filed: October 20, 2017
    Publication date: February 8, 2018
    Inventors: Dominik Feuerbach, Baltazar Gomez-Mancilla, Yunsheng He, Donald Johns, Cristina Lopez-Lopez, Kevin Hall McAllister, Nicole Pezous, Lisa Sandford, Markus Weiss
  • Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists
    Patent number: 9849117
    Abstract: The present invention relates to 1-aza-bicycloalkyl derivatives of formula I, wherein X is CH2 or a single bond; Y is a group of formula and wherein R has the meanings as defined in the specification, which compounds are alpha 7 nicotinic acetylcholine receptor (nAChR) agonists; to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
    Type: Grant
    Filed: January 4, 2017
    Date of Patent: December 26, 2017
    Assignee: Novartis AG
    Inventors: Dominik Feuerbach, Konstanze Hurth, Timothy John Ritchie, Rochdi Bouhelal
  • USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS
    Publication number: 20170348294
    Abstract: The invention concerns the use of certain alpha 7 nicotinic acetylcholine receptor agonist for the facilitation of emergence from general anesthesia.
    Type: Application
    Filed: August 25, 2017
    Publication date: December 7, 2017
    Inventors: Markus FENDT, Dominik FEUERBACH, Sjoerd Jehannes FINNEMA, Baltazar GOMEZ-MANCILLA, Christer HALLDIN, Donald JOHNS, Cristina LOPEZ-LOPEZ, Kevin Hall MCALLISTER, Judit SOVAGO, Markus WEISS
  • Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment
    Patent number: 9828642
    Abstract: The invention provides methods for predicting therapeutic responsiveness of a subject suffering from cognitive impairments or dysfunctions, psychotic and/or neurodegenerative disorders to an alpha 7 nicotinic acetylcholine receptor activator treatment.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: November 28, 2017
    Assignee: Novartis AG
    Inventors: Dominik Feuerbach, Baltazar Gomez-Mancilla, Yunsheng He, Donald Johns, Cristina Lopez-Lopez, Kevin Hall McAllister, Nicole Pezous, Lisa Sandford, Markus Weiss
  • Substituted quinuclidines as alpha 7-nicotinic acetylcholine receptor activity modulators
    Patent number: 9657010
    Abstract: The present invention relates to 1-aza-bicycloalkyl derivatives of formula (I) wherein the substituents are as defined in the specification, to processes for their production, their use as pharmaceuticals in the prevention and treatment of psychotic and neurodegenerative disorders. The claimed compounds act as nicotinic acetylcholine receptors (NACHR) ligands.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: May 23, 2017
    Assignee: Novartis AG
    Inventors: Dominik Feuerbach, Mathias Frederiksen, Konstanze Hurth, Bernard Lucien Roy
  • AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS
    Publication number: 20170112814
    Abstract: The present invention relates to 1-aza-bicycloalkyl derivatives of formula I, wherein X is CH2 or a single bond; Y is a group of formula and wherein R has the meanings as defined in the specification, which compounds are alpha 7 nicotinic acetylcholine receptor (nAChR) agonists; to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
    Type: Application
    Filed: January 4, 2017
    Publication date: April 27, 2017
    Inventors: Dominik Feuerbach, Konstanze Hurth, Timothy John Ritchie, Rochdi Bouhelal